Business
Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform
Seamless ordering and receipt of genomic test results directly in patient records streamlines clinician access to precision medicine tools PALO ALTO, Calif.
About this update from Guardant Health, Inc.
[{"type":"text","content":"\nSeamless ordering and receipt of genomic test results directly in patient records streamlines clinician access to precision medicine tools\n\n\n PALO ALTO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology and closing the gap between research and care, today announced an initiative to integrate Guardant’s comprehensive genomic profiling tests within Flatiron’s OncoEMR®, a leading cloud-based electronic medical record (EMR) tool.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231031158337/en/\nThe integration simplifies access to critical data that informs patient care decisions for over 2,000 clinicians within the Flatiron network, which includes more than 800 community-based cancer care locations across the U.S. Users can easily submit Guardant Health test orders, track real-time status updates, and receive the test results directly in the patient record, via the Molecular Profiling Integration on the OncoEMR platform. This streamlines workflows for physicians and saves time in the ordering process. Clinicians use the test results to help select the best treatment for patients with advanced cancer and monitor for recurrence in patients with early-stage cancer.\n\n\n“Genomic profiling provides critical data that helps oncologists make timely and informed decisions about personalized treatment plans for their patients,” said Chris Freeman, Guardant Health chief commercial officer. “This integration with the OncoEMR platform, which reaches almost 40 percent of U.S. community oncologists, will simplify access to our tests and enable a significant step forward in our mission to conquer cancer with data.”\n\n\nThe companies beta-tested the integration at multiple oncology practice sites across the U.S. earlier this year and saw >75% utilization of the integration vs. traditional ordering workflows. Guardant Health and Flatiron Health plan to roll the integration out to the entire OncoEMR network over the next several months. Practices in the network will have access to Guardant Health’s entire portfolio of advanced blood and tissue tests for early- and advanced-stage canc...